{"filing":{"accession_number":"0001628280-26-043559","cik":"0001655759","ticker":"ARVN","company_name":"ARVINAS, INC.","form":"8-K","filing_date":"2026-06-16","report_date":null,"primary_document":"arvn-20260611.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1655759/000162828026043559/arvn-20260611.htm"},"events":[{"id":11334,"run_id":9950,"accession_number":"0001628280-26-043559","anchor_item_number":"8.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"summary":"Arvinas and Pfizer entered into a license agreement with Rigel for exclusive global development, manufacturing and commercialization rights for VEPPANU, which became effective on June 11, 2026 following HSR clearance. The transaction involves a $70 million upfront payment, up to $320 million in contingent milestone payments, and tiered royalties, representing a material disposition of development and commercialization rights that would significantly affect investor assessment of the company's asset portfolio and revenue streams.","company_name":"ARVINAS, INC.","ticker":"ARVN","filing_date":"2026-06-16","form":"8-K","submitted_at":null,"items":[{"id":7899,"accession_number":"0001628280-26-043559","item_number":"8.01","item_title":"Other Events.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"Arvinas and Pfizer entered into a license agreement with Rigel for exclusive global development, manufacturing and commercialization rights for VEPPANU, which became effective on June 11, 2026 following HSR clearance. The transaction involves a $70 million upfront payment, up to $320 million in contingent milestone payments, and tiered royalties, representing a material disposition of development and commercialization rights that would significantly affect investor assessment of the company's asset portfolio and revenue streams.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-16T20:31:09.699572+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":7899,"accession_number":"0001628280-26-043559","item_number":"8.01","item_title":"Other Events.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"Arvinas and Pfizer entered into a license agreement with Rigel for exclusive global development, manufacturing and commercialization rights for VEPPANU, which became effective on June 11, 2026 following HSR clearance. The transaction involves a $70 million upfront payment, up to $320 million in contingent milestone payments, and tiered royalties, representing a material disposition of development and commercialization rights that would significantly affect investor assessment of the company's asset portfolio and revenue streams.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-16T20:31:09.699572+00:00","company_name":"ARVINAS, INC.","ticker":"ARVN","filing_date":"2026-06-16"}]}